<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01466231</url>
  </required_header>
  <id_info>
    <org_study_id>GCTSK002</org_study_id>
    <nct_id>NCT01466231</nct_id>
  </id_info>
  <brief_title>Everolimus in Refractory Testicular Germ Cell Cancer</brief_title>
  <official_title>Phase II Study of Everolimus in Refractory Testicular Germ Cell Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Slovakia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Slovakia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Everolimus in refractory testicular germ cell cancer. Everolimus 10 mg /day/ is administered&#xD;
      to the patient until progression, unacceptable toxicity, complete response or inability of&#xD;
      the subject to comply with study requirements. Feasibility of surgical resection will be&#xD;
      assessed after every 2 cycles of the treatment in patients with partial response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment Schedule: Everolimus will be administered at a dose of 10mg/day orally once a day.&#xD;
      One cycle of therapy consists of 28 days.&#xD;
&#xD;
      Estimated duration of treatment: Until progression, unacceptable toxicity, complete response&#xD;
      or inability of the subject to comply with study requirements.&#xD;
&#xD;
      Feasibility of surgical resection will be assessed after every 2 cycles of the treatment in&#xD;
      patients with partial response.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>36 month</time_frame>
    <description>according RECIST criteria version 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Favorable response rate</measure>
    <time_frame>36 month</time_frame>
    <description>complete response with chemotherapy and/or surgery, partial response marker negative.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate</measure>
    <time_frame>36 month</time_frame>
    <description>(complete and partial response and stable disease &gt; 6 months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>36 month</time_frame>
    <description>expressed as median and as 12-weeks post-treatment initiation continuous progression-free survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>36 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of grade III and IV adverse events</measure>
    <time_frame>36 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between clinical outcome and biomarkers</measure>
    <time_frame>36 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum tumor markers response</measure>
    <time_frame>36 month</time_frame>
    <description>&gt;90% decline of AFP and/or HCG</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Germ Cell Tumor</condition>
  <arm_group>
    <arm_group_label>everolimus 10 mg po daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>everolimus 10 mg po daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Tablets p.o. 10 mg daily until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements.</description>
    <arm_group_label>everolimus 10 mg po daily</arm_group_label>
    <other_name>Afinitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed written informed consent&#xD;
&#xD;
          2. Men aged 18 years or older&#xD;
&#xD;
          3. ECOG performance status: 0-2,&#xD;
&#xD;
          4. Histological confirmed extracranial primary germ cell cancer, seminoma, or nonseminoma&#xD;
&#xD;
          5. Rising serum markers (i.e., alpha-fetoprotein and human chorionic gonadotropin) on&#xD;
             sequential measurement or biopsy-proven unresectable germ cell cancer&#xD;
&#xD;
          6. Refractory GCTs e.g. patients relapsing after high-dose chemotherapy or for patients&#xD;
             non fit enough for high-dose chemotherapy&#xD;
&#xD;
          7. Primary mediastinal GCTs in first relapse&#xD;
&#xD;
          8. Patient's disease must not be amenable to cure with either surgery or chemotherapy in&#xD;
             the opinion of investigator,&#xD;
&#xD;
          9. Measurable disease radiological&#xD;
&#xD;
         10. Adequate hematologic function defined by WBC &gt; 4000/mm3, platelet count &gt; 100 000/mm3&#xD;
             and hemoglobin level &gt; 9g/dl.&#xD;
&#xD;
         11. Adequate liver function defined by a total bilirubin level &lt; 1.5 ULN, and ALT, AST &lt;&#xD;
             2,5 ULN and adequate renal function defined by serum creatinine â‰¤ 1.5 x ULN.&#xD;
&#xD;
         12. At least 2 weeks must have elapsed since the last radiotherapy and/or chemotherapy&#xD;
             before study entry,&#xD;
&#xD;
         13. At least 4 weeks must have elapsed since the last major surgery&#xD;
&#xD;
         14. Complete recovery from prior surgery, and/or reduction of all adverse events from&#xD;
             previous systemic therapy or radiotherapy to grade 1,&#xD;
&#xD;
         15. Absence of any psychological, familial, sociological or geographical condition&#xD;
             potentially hampering compliance with the study protocol and follow-up schedule, -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who do not fit inclusion criteria,&#xD;
&#xD;
          2. Other prior malignancy except successfully treated non melanoma skin cancer&#xD;
&#xD;
          3. Prior treatment with mTOR inhibitor&#xD;
&#xD;
          4. No other concurrent approved or investigational anticancer treatment, including&#xD;
             surgery, radiotherapy, chemotherapy, biologic-response modifiers, hormone therapy, or&#xD;
             immunotherapy&#xD;
&#xD;
          5. Female patients,&#xD;
&#xD;
          6. Patients infected by the Human Immunodeficiency Virus (HIV),&#xD;
&#xD;
          7. Patients with other severe acute or chronic medical condition, or laboratory&#xD;
             abnormality that would impair, in the judgment of investigator, excess risk associated&#xD;
             with study treatment, or which, in judgment of the investigator, would make the&#xD;
             patient inappropriate for entry into this study,&#xD;
&#xD;
          8. Inability of oral intake, or drug absorption (e.g. malabsorption syndrome)&#xD;
&#xD;
          9. Hypersensitivity to any compound of the drug,&#xD;
&#xD;
         10. Sexually active men not using effective birth control if their partners are women of&#xD;
             child-bearing potential.&#xD;
&#xD;
         11. Patients with active CNS metastasis&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jozef Mardiak, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michal Mego, Ass.prof.</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute, Slovakia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Bratislava</city>
        <zip>83310</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>October 31, 2011</study_first_submitted>
  <study_first_submitted_qc>November 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2011</study_first_posted>
  <last_update_submitted>January 11, 2016</last_update_submitted>
  <last_update_submitted_qc>January 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>refractory germ cell cancer</keyword>
  <keyword>everolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Testicular Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

